Segall Bryant & Hamill’s Niagen Bioscience NAGE Stock Holding History

Segall Bryant & Hamill’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-17,500	Closed	-$57K	–	826
2020 Q1	$57K	Buy	17,500 +2,000	+13%	+$7.68K	﹤0.01%	772
2019 Q4	$67K	Sell	15,500 -5,500	-26%	-$19.5K	﹤0.01%	809
2019 Q3	$83K	Hold	21,000	–	–	﹤0.01%	807
2019 Q2	$98K	Buy	21,000 +1,000	+5%	+$4.27K	﹤0.01%	798
2019 Q1	$84K	Sell	20,000 -2,000	-9%	-$7.21K	﹤0.01%	808
2018 Q4	$75K	Hold	22,000	–	–	﹤0.01%	805
2018 Q3	$94K	Sell	22,000 -3,000	-12%	-$12.9K	﹤0.01%	829
2018 Q2	$93K	Hold	25,000	–	–	﹤0.01%	837
2018 Q1	$105K	Hold	25,000	–	–	﹤0.01%	597
2017 Q4	$147K	Sell	25,000 -5,000	-17%	-$27K	﹤0.01%	557
2017 Q3	$129K	Sell	30,000 -8,834	-23%	-$32.3K	﹤0.01%	561
2017 Q2	$148K	Hold	38,834	–	–	﹤0.01%	543
2017 Q1	$104K	Buy	38,834 +133	+0.3%	+$377	﹤0.01%	541
2016 Q4	$128K	Hold	38,701	–	–	﹤0.01%	529
2016 Q3	$115K	Buy	38,701 +1,034	+3%	+$3.8K	﹤0.01%	540
2016 Q2	$156K	Buy	+37,667	New	+$178K	﹤0.01%	532

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sycale Advisors New York $201M AUM 2.35% 1-Year Est. Return

Segall Bryant & Hamill's NAGE Position: Q2 2020 in Review

Segall Bryant & Hamill sold out of Niagen Bioscience (NAGE) in Q2 2020, closing a stake of 17,500 shares — an estimated $57K sold.

Segall Bryant & Hamill first reported a position in NAGE in Q2 2016 and held it in 16 quarters. The position peaked at $156K in Q2 2016. 66 funds tracked by Wall St. Rank hold NAGE as of Q2 2020.

Segall Bryant & Hamill reported no remaining Niagen Bioscience position as of Q2 2020 after selling out during the quarter.
Segall Bryant & Hamill sold 17,500 Niagen Bioscience shares in Q2 2020, an estimated $57K.
Segall Bryant & Hamill first reported a position in Niagen Bioscience in Q2 2016 and held it in 16 quarters.
Segall Bryant & Hamill's Niagen Bioscience position peaked at $156K in Q2 2016.
66 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2020.

Based on Segall Bryant & Hamill's 13F filing for Q2 2020, filed 14 Aug 2020.